Dr. Reddy's Laboratories Ltd Common Stock (RDY)

Let’s dive into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) using Peter Lynch’s key investing principles, from earnings growth and debt levels to long-term scalability and valuation.

Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

Exploring DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)'s quality characteristics.

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions.

The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio?

Dr. Reddy's Q2 2025 report shows a revenue boost to $957 million, fueled by global generics. North American sales rose 17% year-over-year.

Dr Reddy's Laboratories is progressing lower within a counter trend zigzag to terminate Minor Wave 4 Grey around 5600 levels.

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) may be suited for quality investing, we'll explore why in this article.

100% technical buy signals 12 new highs and up 10.76% in the last month 38.40+ Weighted Alpha

Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level.

On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.

Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with potential royalties on sales also available.

On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) can be considered a quality stock. Here's why.

On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76.

Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth areas.

Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections.

RDY stock results show that Dr Reddy's Laboratories beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.

Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by 2026-2032, these generics aim to address India's rising obesity and diabetes concerns, anticipating substantial market growth in the next decade.

Reasonable Growth, Debt Levels, and a High ROIC Make DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Appealing to Quality Investors.

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Journey Medical Corporation (NASDAQ: DERM) shares are trading lower after the company announced topline results from the two Phase 3 trials, evaluating Minocycline Hydrochloride Modified Release Capsules (DFD-29) for adult patients with moderate-to-severe 

Journey Medical Corporation (NASDAQ: DERM) announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the